Scarica l'app Stockscreener
1.35
4.65%
0.06
Dopo l'orario di chiusura:
1.35
Precedente Chiudi:
$1.29
Aprire:
$1.3
Volume 24 ore:
128.96K
Relative Volume:
0.47
Capitalizzazione di mercato:
$9.17M
Reddito:
$5.64M
Utile/perdita netta:
$-23.88M
Rapporto P/E:
-2.4545
EPS:
-0.55
Flusso di cassa netto:
$-22.36M
1 W Prestazione:
-1.46%
1M Prestazione:
-18.18%
6M Prestazione:
-78.05%
1 anno Prestazione:
-84.25%
Intervallo 1D:
$1.30
$1.44
Intervallo di 1 settimana:
$1.20
$1.44
Portata 52W:
$1.20
$10.40
Evogene Ltd Stock (EVGN) Company Profile
Confronta EVGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.35 | 9.17M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-08 | Iniziato | ROTH Capital | Buy |
| 2021-07-29 | Iniziato | Aegis Capital | Buy |
| 2020-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Iniziato | Oppenheimer | Outperform |
Evogene Ltd Borsa (EVGN) Ultime notizie
Evogene Ltd. (NASDAQ:EVGN) Position Lessened by BNP Paribas Financial Markets - Defense World
Evogene (NASDAQ:EVGN) Now Covered by StockNews.com - Defense World
Evogene (NASDAQ:EVGN) vs. N2OFF (NASDAQ:NITO) Financial Review - Defense World
Evogene stock touches 52-week low at $1.25 amid market challenges - Investing.com Canada
Evogene stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
Minichromosomal Technology in Agriculture Market Size - openPR
Marrone Bio Innovations : Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration - Marketscreener.com
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification - GuruFocus.com
Evogene Schedules Second Quarter 2024 Financial Results Release - The Eastern Progress Online
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials - The Eastern Progress Online
Evogene stock touches 52-week low at $1.44 amid market challenges - Investing.com Nigeria
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024 - GuruFocus.com
Evogene Unit Receives Notice Of Termination Of Licensing Agreement With Corteva For Bio Fungicide Lead Candidates - XM
Evogene Q3 2024 Earnings Preview - MSN
Ventum Financial Issues Pessimistic Forecast for Evogene (TSE:EVGN) Stock Price - Defense World
Evogene Ltd. (NASDAQ:EVGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - Investing.com Canada
Evogene Schedules Third Quarter 2024 Financial Results Release - GuruFocus.com
Casterra Announces a Key Milestone in its Operational Expansion - GuruFocus.com
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Evogene earnings missed by $0.30, revenue fell short of estimates - Investing.com India
Evogene Reports Third Quarter 2024 Financial Results - The Malaysian Reserve
Evogene: Q3 Earnings Snapshot - San Antonio Express-News
Evogene Sees Revenue Growth and Expands AI Collaboration - TipRanks
SEC Form 424B3 filed by Evogene Ltd - Quantisnow
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results - Marketscreener.com
Evogene stock hits 52-week low at $1.7 amid market challenges - Investing.com India
Evogene (EVGN) Set to Announce Quarterly Earnings on Thursday - Defense World
Lavie Bio Announces Commercial Expansion of Yalos As Seed Treatment for Soybean - Agribusiness Global
Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials - Krishak Jagat English
Evogene subsidiary Lavie Bio announces commercial expansion of Yalos treatment - TipRanks
Evogene (EVGN) to Report Q3 2024 Results, Hosts Virtual Conference Call Nov 21 | EVGN Stock News - StockTitan
II: Exploring 🧭 TechBio - substack.com
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design - Krishak Jagat English
Evogene and Google Cloud Partner to Develop AI Foundation Model for Drug Discovery - HIT Consultant
Evogene stock hits 52-week low at $2.13 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com
Evogene partners with Google Cloud for AI-driven molecule design By Investing.com - Investing.com Australia
Evogene partners with Google Cloud for AI-driven molecule design - Investing.com India
Biomica to Present at Digestive Disease Week (DDW) Conference 20 - GuruFocus.com
Evogene announces collaboration with Google Cloud - MSN
Evogene Ltd Azioni (EVGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):